CD274 and autoimmune disease: It should be kept in mind that clinical studies constituting the basis for the registration of PD-1 or PD-L1 inhibitors usually did not include indications for use in patients with a history of lung cancer concurrent with autoimmune disease or patients after organ transplants in whom the use of immunosuppressive therapy could lead to immune system dysfunction significantly affecting the detection and elimination of cancer cells (1–6).